** Shares of drug developer Sagimet Biosciences SGMT.O rise 52% to $5.53 premarket
** SGMT says its oral acne drug, denifanstat, met the main goals in a late-stage trial conducted by its Chinese partner Ascletis 1672.HK
** Denifanstat showed 33.2% treatment success rate versus 14.6% for placebo
** Denifanstat works by inhibiting the production of sebum, a key contributor to acne, through a novel mechanism of action, co says
** The drug reduced total acne lesions by 57.4% compared to 35.4% with placebo
** Ascletis plans to submit denifanstat for approval to Chinese regulators
** As of last close, stock down 19.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。